Home
/
Outlook Therapeutics, Inc.
/
Financials
/
Quarterly
Outlook Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Outlook Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2020
Jun 30, 2019
$583.8K
Aug 14, 2020
Q2
2020
Mar 31, 2019
$641.1K
May 15, 2020
Q1
2020
Dec 31, 2018
$1.07M
Feb 14, 2020
Q3
2019
Jun 30, 2018
$771.9K
Aug 14, 2019
Q2
2019
Mar 31, 2018
$771.9K
May 15, 2019
Q1
2019
Dec 31, 2017
$771.9K
Feb 14, 2019
Q3
2018
Jun 30, 2017
$303.1K
Aug 14, 2018
Q2
2018
Mar 31, 2017
$303.1K
May 15, 2018
Q1
2018
Dec 31, 2016
$303.1K
Feb 14, 2018
Q3
2017
Jun 30, 2016
$494.9K
Aug 14, 2017
Q2
2017
Mar 31, 2016
$994.9K
May 15, 2017
Q1
2017
Dec 31, 2015
$994.9K
Feb 14, 2017
Q3
2016
Jun 30, 2015
$1.29M
Aug 15, 2016
Q2
2016
Mar 31, 2015
$494.9K
Jun 27, 2016
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Jun 30, 2025
$1.51M
Aug 14, 2025
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2026
Dec 31, 2025
($23.06M)
Feb 17, 2026
Q3
2025
Jun 30, 2025
($20.15M)
Aug 14, 2025
Q2
2025
Mar 31, 2025
($46.36M)
May 15, 2025
Q3
2025
Mar 31, 2025
($46.36M)
Aug 14, 2025
Q1
2026
Dec 31, 2024
$17.38M
Feb 17, 2026
Q2
2025
Dec 31, 2024
$17.38M
May 15, 2025
Q3
2025
Dec 31, 2024
$17.38M
Aug 14, 2025
Q3
2025
Jun 30, 2024
$44.41M
Aug 14, 2025
Q3
2025
Mar 31, 2024
($114.29M)
Aug 14, 2025
Q2
2025
Mar 31, 2024
($114.29M)
May 15, 2025
Q1
2025
Dec 31, 2023
($11.18M)
Feb 14, 2025
Q3
2025
Dec 31, 2023
($11.18M)
Aug 14, 2025
Q2
2025
Dec 31, 2023
($11.18M)
May 15, 2025
Q3
2024
Jun 30, 2023
($20.68M)
Aug 14, 2024
Q2
2024
Mar 31, 2023
($6.65M)
May 15, 2024
Q3
2024
Mar 31, 2023
($6.65M)
Aug 14, 2024
Q1
2024
Dec 31, 2022
($18.66M)
Feb 14, 2024
Q3
2024
Dec 31, 2022
($18.66M)
Aug 14, 2024
Q2
2024
Dec 31, 2022
($18.66M)
May 15, 2024
Q3
2023
Jun 30, 2022
($17.54M)
Aug 14, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2026
Dec 31, 2025
($13.48M)
Feb 17, 2026
Q3
2025
Jun 30, 2025
($15.75M)
Aug 14, 2025
Q2
2025
Mar 31, 2025
($12.39M)
May 15, 2025
Q1
2026
Dec 31, 2024
($21.61M)
Feb 17, 2026
Q3
2025
Jun 30, 2024
($19.56M)
Aug 14, 2025
Q2
2025
Mar 31, 2024
($18.94M)
May 15, 2025
Q1
2025
Dec 31, 2023
($10.32M)
Feb 14, 2025
Q3
2024
Jun 30, 2023
($18.14M)
Aug 14, 2024
Q2
2024
Mar 31, 2023
($6.84M)
May 15, 2024
Q1
2024
Dec 31, 2022
($15.69M)
Feb 14, 2024
Q3
2023
Jun 30, 2022
($17.02M)
Aug 14, 2023
Q2
2023
Mar 31, 2022
($18.91M)
May 15, 2023
Q1
2023
Dec 31, 2021
($13.15M)
Feb 14, 2023
Q3
2022
Jun 30, 2021
($11.47M)
Aug 10, 2022
Q2
2022
Mar 31, 2021
($12.63M)
May 13, 2022
Q1
2022
Dec 31, 2020
($14.19M)
Feb 14, 2022
Q3
2021
Jun 30, 2020
($11.88M)
Aug 13, 2021
Q2
2021
Mar 31, 2020
($6.76M)
May 14, 2021
Q1
2021
Dec 31, 2019
($8.18M)
Feb 16, 2021
Q3
2020
Jun 30, 2019
($5.64M)
Aug 14, 2020